Literature DB >> 19903830

Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.

Liliya N Kirpotina1, Andrei I Khlebnikov, Igor A Schepetkin, Richard D Ye, Marie-Josèphe Rabiet, Mark A Jutila, Mark T Quinn.   

Abstract

N-formyl peptide receptor (FPR1) and N-formyl peptide receptor-like 1 (FPRL1, now known as FPR2) are G protein-coupled receptors involved in host defense and sensing cellular dysfunction. Because of the potential for FPR1/FPR2 as a therapeutic target, our recent high-throughput screening efforts have focused on the identification of unique nonpeptide agonists of FPR1/FPR2. In the present studies, we screened a chemolibrary of drug-like molecules for their ability to induce intracellular calcium mobilization in RBL-2H3 cells transfected with human FPR1 or FPR2. Screening of these compounds resulted in the identification of novel and potent agonists that activated both FPR1 and FPR2, as well as compounds that were specific for either FPR1 or FPR2 with EC(50) values in the low micromolar range. Specificity of the compounds was supported by analysis of calcium mobilization in HL-60 cells transfected with human FPR1 and FPR2. In addition, all but one agonist activated intracellular calcium flux and chemotaxis in human neutrophils, irrespective of agonist specificity for FPR1 or FPR2. Molecular modeling of the group of FPR1 and FPR2 agonists using field point methodology allowed us to create pharmacophore models for ligand binding sites and formulate requirements for these specific N-formyl peptide receptor agonists. These studies further demonstrate that agonists of FPR1/FPR2 include compounds with wide chemical diversity and that analysis of such compounds can enhance our understanding of their ligand/receptor interaction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903830      PMCID: PMC2812066          DOI: 10.1124/mol.109.060673

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  35 in total

Review 1.  Innate immune responses to infection.

Authors:  Michael F Tosi
Journal:  J Allergy Clin Immunol       Date:  2005-08       Impact factor: 10.793

2.  Duplex high-throughput flow cytometry screen identifies two novel formylpeptide receptor family probes.

Authors:  Susan M Young; Cristian M Bologa; Dan Fara; Bj K Bryant; Juan Jacob Strouse; Jeffrey B Arterburn; Richard D Ye; Tudor I Oprea; Eric R Prossnitz; Larry A Sklar; Bruce S Edwards
Journal:  Cytometry A       Date:  2009-03       Impact factor: 4.355

3.  Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa.

Authors:  M Böhm; J St rzebecher; G Klebe
Journal:  J Med Chem       Date:  1999-02-11       Impact factor: 7.446

4.  Molecular field technology applied to virtual screening and finding the bioactive conformation.

Authors:  Tim Cheeseright; Mark Mackey Phd; Sally Rose Phd; Andy Vinter Phd
Journal:  Expert Opin Drug Discov       Date:  2007-01       Impact factor: 6.098

5.  Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents.

Authors:  Roland W Bürli; Han Xu; Xiaoming Zou; Kristine Muller; Jennifer Golden; Mike Frohn; Matthew Adlam; Matthew H Plant; Min Wong; Michele McElvain; Kelly Regal; Vellarkad N Viswanadhan; Philip Tagari; Randall Hungate
Journal:  Bioorg Med Chem Lett       Date:  2006-05-11       Impact factor: 2.823

6.  Identification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Jun Tian; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2008-05-05       Impact factor: 4.436

7.  Rationalizing the activities of diverse cholecystokinin 2 receptor antagonists using molecular field points.

Authors:  Caroline M R Low; J G Vinter
Journal:  J Med Chem       Date:  2008-01-18       Impact factor: 7.446

Review 8.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

9.  A novel nonpeptide ligand for formyl peptide receptor-like 1.

Authors:  Masakatsu Nanamori; Xiyuan Cheng; Jianghua Mei; Hairong Sang; Yunxia Xuan; Caihong Zhou; Ming-Wei Wang; Richard D Ye
Journal:  Mol Pharmacol       Date:  2004-08-12       Impact factor: 4.436

10.  Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor.

Authors:  J L Gao; E J Lee; P M Murphy
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

View more
  28 in total

1.  Molecular docking of 2-(benzimidazol-2-ylthio)-N-phenylacetamide-derived small-molecule agonists of human formyl peptide receptor 1.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Liliya N Kirpotina; Lars Brive; Claes Dahlgren; Mark A Jutila; Mark T Quinn
Journal:  J Mol Model       Date:  2011-11-30       Impact factor: 1.810

2.  Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2010-09-15       Impact factor: 6.514

3.  Sublytic concentrations of Staphylococcus aureus Panton-Valentine leukocidin alter human PMN gene expression and enhance bactericidal capacity.

Authors:  Shawna F Graves; Scott D Kobayashi; Kevin R Braughton; Adeline R Whitney; Daniel E Sturdevant; Devon L Rasmussen; Liliya N Kirpotina; Mark T Quinn; Frank R DeLeo
Journal:  J Leukoc Biol       Date:  2012-05-11       Impact factor: 4.962

4.  Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries.

Authors:  Clemencia Pinilla; Bruce S Edwards; Jon R Appel; Tina Yates-Gibbins; Marc A Giulianotti; Jose L Medina-Franco; Susan M Young; Radleigh G Santos; Larry A Sklar; Richard A Houghten
Journal:  Mol Pharmacol       Date:  2013-06-20       Impact factor: 4.436

5.  Structural determinants for the interaction of formyl peptide receptor 2 with peptide ligands.

Authors:  Hui-Qiong He; Erica L Troksa; Gianluigi Caltabiano; Leonardo Pardo; Richard D Ye
Journal:  J Biol Chem       Date:  2013-11-27       Impact factor: 5.157

6.  Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Ni Cheng; Richard D Ye; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2014-10-17       Impact factor: 5.858

7.  4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.

Authors:  Liliya N Kirpotina; Igor A Schepetkin; Andrei I Khlebnikov; Olga I Ruban; Yunjun Ge; Richard D Ye; Douglas J Kominsky; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2017-07-08       Impact factor: 5.858

Review 8.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

9.  Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Tracey S Hanks; Irina Kochetkova; David W Pascual; Mark A Jutila; Mark T Quinn
Journal:  Mol Pharmacol       Date:  2012-03-20       Impact factor: 4.436

10.  2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2016-04-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.